Date published: 2026-4-27

1-800-457-3801

SCBT Portrait Logo
Seach Input

DLK Inhibitors

Dual Leucine Zipper Kinase (DLK) inhibitors are a class of chemical compounds that selectively target and inhibit the activity of the DLK enzyme, which is a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family. DLK, also known as MAP3K12, plays a critical role in cellular signaling pathways, particularly those related to stress responses and neuronal development. DLK is a key regulator of the c-Jun N-terminal kinase (JNK) pathway, which is involved in a variety of cellular processes, including apoptosis, inflammation, and cellular differentiation. The inhibition of DLK disrupts this pathway, leading to alterations in downstream signaling cascades that can affect various cellular functions. DLK inhibitors are typically designed to bind to the ATP-binding site of the kinase, thereby preventing its phosphorylation and activation. These inhibitors can be highly specific, with some designed to target DLK with minimal effects on other kinases within the MAP3K family, ensuring a focused modulation of the DLK-related pathways. The chemical structures of DLK inhibitors are diverse, often characterized by heterocyclic cores that can engage in key interactions with the DLK active site. Common structural motifs include pyrimidines, quinolines, and thiazoles, which provide a scaffold for further functionalization to enhance selectivity and potency. The development of DLK inhibitors involves extensive structure-activity relationship (SAR) studies to optimize binding affinity and selectivity. These studies help identify crucial interactions between the inhibitor and the enzyme, such as hydrogen bonds, hydrophobic interactions, and π-π stacking. Additionally, DLK inhibitors are often designed to possess favorable pharmacokinetic properties, such as good solubility, stability, and membrane permeability, to ensure their effective action within the cellular environment. The exploration of DLK inhibitors also includes studies on their potential off-target effects, metabolic stability, and potential for bioaccumulation, which are essential for understanding the full scope of their impact on biological systems.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Inhibits mTOR, a kinase involved in the same signaling pathways as DLK1, leading to reduced DLK1 mediated cellular responses.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

Histone deacetylase inhibitor that can change gene expression patterns, potentially affecting DLK1 signaling.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

MEK inhibitor, affects the MAPK/ERK pathway which is downstream of DLK1, leading to an indirect inhibition of DLK1 signaling.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

p38 MAPK inhibitor, impacts one of the signaling pathways downstream of DLK1, thereby inhibiting its functional effects.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Another PI3K inhibitor, disrupts DLK1 related signaling pathways.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$111.00
$357.00
8
(0)

Modifies immune response and cytokine production, indirectly influencing DLK1 signaling pathways.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor, affects protein turnover and can indirectly impact DLK1 signaling pathways.

Cyclosporin A

59865-13-3sc-3503
sc-3503-CW
sc-3503A
sc-3503B
sc-3503C
sc-3503D
100 mg
100 mg
500 mg
10 g
25 g
100 g
$63.00
$92.00
$250.00
$485.00
$1035.00
$2141.00
69
(5)

Immunomodulatory drug that can alter DLK1 related signaling pathways in immune cells.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

Inhibits MEK, part of the MAPK/ERK pathway, thus indirectly reducing DLK1 signaling.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

JNK inhibitor, affects a pathway that is potentially involved in DLK1 signaling, leading to an indirect reduction of its activity.